Successful treatment of bubonic plague

Share Post :
Row of microscopes in a lab

A groundbreaking clinical trial has provided conclusive evidence to support WHO guidance that a simple, affordable oral antibiotic can improve bubonic plague treatment worldwide. The IMASOY trail, funded by the Foreign Commonwealth and Development Office and Wellcome, represents the first conclusive randomised controlled trial to provide conclusive evidence on the efficacy and safety of treatments for this disease. 

Despite declining cases globally, bubonic plague continues to pose a threat across most continents, with Madagascar accounting for over 80% of detected cases worldwide. Current treatment involves regimens with limited clinical evidence, often requiring expensive injectable antibiotics and hospital stays.

The UK-Madagascan research collaboration enrolled and treated 450 suspected plague cases, 220 of whom were confirmed or probable by laboratory tests. comparing two treatment approaches. The standard protocol involved a three-day course of injectable aminoglycoside followed by 7 days of oral ciprofloxacin. This was tested against a simplified ten-day course of ciprofloxacin alone.
Results demonstrated that the ciprofloxacin-only treatment proved highly effective and safe whilst costing just one-tenth of existing treatment. Beyond clinical effectiveness, researchers conducted a qualitative study examining whether Madagascan clinicians would accept this simplified approach in practice. This comprehensive evaluation ensures the findings can translate into real-world healthcare improvements.

The trial represents a collaborative effort between leading institutions: ISARIC at the University of Oxford, Institut Pasteur de Madagascar, the Centre d’infectiologie Charles Mérieux, and the London School of Hygiene and Tropical Medicine. This international partnership demonstrates how strategic research funding can address neglected diseases affecting vulnerable populations.

Check the ISARIC research page for further information on the bubonic plague treatment and clinical trial.

See more

How AI can help survivors in low-resource settings access justice

Justice systems in low-resource and conflict-affected settings are often stretched to breaking point. In Malawi, for example, fewer than 800 lawyers serve a population of 22 million, and legal aid caseloads run into the tens of thousands

RIDE: generating evidence for sustainable transport in developing economies

A major new international research and policy partnership is helping to shape the future of sustainable transport across low and middle-income countries.

Two decades of research: the Young Lives study

Young Lives is a unique longitudinal research programme that has followed 12,000 young people in Ethiopia, India, Peru and Vietnam – from infancy to adulthood – for more than 2 decades.

Lessons from the frontier of AI in international development

Artificial intelligence is often presented as a new frontier for international development. But the Frontier Tech Hub’s 4-part newsletter series, On the Frontier of AI, tells a more grounded and useful story: AI is not new, not only about large language models, and not useful unless the right data, infrastructure, institutions and safeguards are in place.